RUBY News and Press, Rubius Therapeutics Inc. From 02/25/22

Rubius Therapeutics press release (NASDAQ:RUBY): Q4 GAAP EPS of -$0.61 misses by $0.02. As of December 31, 2021, cash and cash equivalents were $225.8M as compared to $176.3M in cash, cash equivalents and investments as of December 31, 2020, For further details see: Rubius Therapeutics ...

First Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022 Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response. Clin...

Gainers: Cumulus Media (NASDAQ:CMLS) +5%. HOOKIPA Pharma  (NASDAQ:HOOK) +4%. KemPharm (NASDAQ:KMPH) +4%. Anghami  (NASDAQ:ANGH) +4%. Editas Medicine (NASDAQ:EDIT) +4%. Losers: Homology Medicines (NASDAQ:FIXX) -31%. Consumer Portfolio Services (NASDAQ:CPSS) -...

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT PR Newswire CAMBRIDGE, Mass. , Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdepende...

CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this event. For further details see: Rubius Therapeutics (RUBY) Investor Presentation IP - Slideshow

CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...

CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...

Continuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Expected in Q1’22 Initial Clinical Results Expected from the Phase 1 Clinical ...

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...